Subscribe
shutterstock_1425318470_photobyphm
Photobyphm / Shutterstock.com
5 March 2020AmericasSarah Morgan

Sanofi unit takes CSL to court over haemophilia therapy

Biotech company Bioverativ has accused CSL Behring of infringing three patents covering its haemophilia B treatment Alprolix (coagulation factor IX (Recombinant), Fc fusion protein).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Sanofi to buy Bioverativ for $11.6bn
23 January 2018   Paris-based Sanofi has revealed plans to acquire Bioverativ, a US-based biotech company focused on haemophilia treatments.
Americas
USITC begins probe into CSL Behring
10 August 2017   The US International Trade Commission has instituted a probe into CSL Behring, a biopharmaceutical company.
Americas
French healthcare company makes $1.2bn AI drug discovery deal
18 August 2022   Partnership with San Francisco-based software biotech initially focuses on compounds for five targets | Company uses machine learning to enable structure-based drug design.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
Sanofi to buy Bioverativ for $11.6bn
23 January 2018   Paris-based Sanofi has revealed plans to acquire Bioverativ, a US-based biotech company focused on haemophilia treatments.
Americas
USITC begins probe into CSL Behring
10 August 2017   The US International Trade Commission has instituted a probe into CSL Behring, a biopharmaceutical company.
Americas
French healthcare company makes $1.2bn AI drug discovery deal
18 August 2022   Partnership with San Francisco-based software biotech initially focuses on compounds for five targets | Company uses machine learning to enable structure-based drug design.

More on this story

Americas
Sanofi to buy Bioverativ for $11.6bn
23 January 2018   Paris-based Sanofi has revealed plans to acquire Bioverativ, a US-based biotech company focused on haemophilia treatments.
Americas
USITC begins probe into CSL Behring
10 August 2017   The US International Trade Commission has instituted a probe into CSL Behring, a biopharmaceutical company.
Americas
French healthcare company makes $1.2bn AI drug discovery deal
18 August 2022   Partnership with San Francisco-based software biotech initially focuses on compounds for five targets | Company uses machine learning to enable structure-based drug design.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York